Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNC-102 in Drug-Induced Tardive Dyskinesia
NCT02064010Phase 2Withdrawn
- Sponsor
- Synchroneuron Inc.
- Start
- Feb 2014
- Primary completion
- Jan 2015
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
A Phase 2 trial of SNC-102 in tardive dyskinesia (TD), sponsored by Synchroneuron Inc.. Planned start Feb 2014; status: withdrawn.
02
Drugs
SNC-102
03
Conditions
tardive dyskinesia (TD)
Beyond the preview
Go deeper on NCT02064010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02064010.